Text Size

Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01300806
First received: February 17, 2010
Last updated: May 20, 2013
Last verified: May 2013
History of Changes
  Purpose

The goal of this research is to assess the impact of the "screening, brief intervention, and referral to treatment" (SBIRT) intervention strategy for harmful substance use among HIV-positive people.


Condition
Substance Use

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • reduced substance use among HIV-positive people [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • technological innovation to improve the quality of medical care [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 210
Study Start Date: July 2010
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
myHERO SBIRT
clinician administered SBIRT

Detailed Description:

The specific aims of the study are:

  1. To assess the feasibility of conducting SBIRT using (1) a patient self-administered intervention embedded in a web-based Personal Health Record (PHR) compared to (2) a provider-administered SBIRT intervention guided by the Electronic Medical Record (EMR) during clinic appointments.
  2. To examine the acceptability of web-based PHRs to conduct and communicate SBIRT compared to EMR-activated SBIRT conducted by clinic staff, from the perspective of the patient and the provider.
  3. To assess the impact of SBIRT on risky drug and alcohol use in an HIV/AIDS population and subsequent effects on sexual risk behaviors and antiretroviral therapy (ART) adherence.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

primary care clinic patients

Criteria

Inclusion Criteria:

  • 18 years of age
  • confirmed prior HIV+ serostatus
  • ability to provide informed consent to be a participant over a 6 month period
  • English or Spanish speaking

Exclusion Criteria:

Inability to answer questions with interviewer assistance. Not receiving primary care in clinic.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01300806

Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Carol Dawson Rose, PhD University of California, San Francisco
  More Information

No publications provided

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01300806     History of Changes
Other Study ID Numbers: 09035355
Study First Received: February 17, 2010
Last Updated: May 20, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Francisco:
HIV
harmful substance use

ClinicalTrials.gov processed this record on June 18, 2013